0000000000705812

AUTHOR

Lars Möller

showing 2 related works from this author

PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the pe…

2015

BACKGROUND/AIMS: The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time.METHODS: Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000.RESULTS: The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, includi…

AdultMalePediatricsmedicine.medical_specialtyReferralEpidemiologyMedizin030209 endocrinology & metabolismGraves' ophthalmopathyTertiary Care Centers03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineEpidemiologymedicinePrevalenceHumansEpidemiology; Orbit; Ophthalmology; Sensory Systems; Cellular and Molecular NeuroscienceProspective StudiesProspective cohort studyReferral and Consultationbusiness.industryThyroid diseaseMiddle Agedmedicine.diseaseSensory SystemsEuropeGraves OphthalmopathyOphthalmologyCohort030221 ophthalmology & optometryObservational studyFemalesense organsPresentation (obstetrics)businessOrbitBritish journal of ophthalmology
researchProduct

Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer.

1999

The DNA-repair protein O(6)-methylguanine-DNA methyltransferase (alkyltransferase; MGMT) is a major determinant of resistance of cells to various alkylating cytostatic drugs. Its expression in tissues is highly variable, indicating complex regulatory mechanisms involved. Transfection-mediated expression of wild-type p53 has been shown to negatively regulate basal promoter activity of MGMT in vitro. To elucidate whether p53 is involved in regulation of MGMT in tumor tissue, we examined MGMT expression and the p53 status of 140 primary ovarian carcinomas and analyzed the data as to the correlation between MGMT and p53, as well as the survival response of the patients after chemotherapy. We sh…

Cancer ResearchPathologymedicine.medical_specialtyMethyltransferaseTime FactorsCyclophosphamidemedicine.medical_treatmentBiologyDisease-Free Survivalchemistry.chemical_compoundO(6)-Methylguanine-DNA MethyltransferasePredictive Value of TestsmedicineHumansneoplasmsNeoplasm StagingRetrospective StudiesOvarian NeoplasmsChemotherapyL-Lactate DehydrogenaseCancermedicine.diseaseGenes p53ImmunohistochemistrySurvival Analysisdigestive system diseasesNitrogen mustardCarboplatinOncologychemistryCancer researchFemaleTumor Suppressor Protein p53Ovarian cancermedicine.drugAlkyltransferaseFollow-Up StudiesInternational journal of cancer
researchProduct